Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Public ClinicalTrials.gov record NCT03134222. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).
Study identification
- NCT ID
- NCT03134222
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 47 participants
Conditions and interventions
Conditions
Interventions
- Lanraplenib Drug
- Filgotinib Drug
- Lanraplenib placebo Drug
- Filgotinib placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 24, 2017 (Actual)
- Primary completion
- Mar 13, 2019 (Actual)
- Completion
- Dec 18, 2019 (Actual)
- Last update posted
- Jun 9, 2020
2017 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 5
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Wallace Rheumatic Studies Center | Beverly Hills | California | 90211 | — |
| St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare | Fullerton | California | 92835 | — |
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| Desert Medical Advances | Palm Desert | California | 92260 | — |
| Medderm Associates | San Diego | California | 92103 | — |
| Inland Rheumatology Clinical Trials | Upland | California | 91786 | — |
| Clinical Research of West Florida, Inc. | Clearwater | Florida | 33765 | — |
| Omega Research Consultants LLC | DeBary | Florida | 32713 | — |
| DJL Clinical Research, PLLC | Charlotte | North Carolina | 28210 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27104 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Metroplex Clinical Research Center | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03134222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2020 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03134222 live on ClinicalTrials.gov.